Bioatla, Inc.
Clinical trials sponsored by Bioatla, Inc., explained in plain language.
-
Experimental drug tested for Tough-to-Treat head and neck cancers
Disease control CompletedThis study tested an experimental drug called ozuriftamab vedotin (BA3021) in people with advanced head and neck cancer that had returned or spread. The main goals were to see if the drug could shrink tumors and how safe it was. It included 42 adults whose cancer was not curable …
Phase: PHASE2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated Apr 02, 2026 09:27 UTC
-
New targeted drug tested for tough-to-treat cancers
Disease control CompletedThis study tested a new drug called mecbotamab vedotin, both by itself and combined with an existing immunotherapy drug (nivolumab), in people with advanced solid tumors, specifically certain types of sarcoma. The main goals were to find safe doses and see if the treatment could …
Phase: PHASE1, PHASE2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New hope for lung cancer patients when standard treatments fail
Disease control CompletedThis study tested a new drug called BA3011, both alone and combined with an immunotherapy drug, for adults with advanced lung cancer that had worsened despite previous treatments. Researchers aimed to see if these approaches were safe and could shrink tumors or slow cancer growth…
Phase: PHASE2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC